Jazz Pharmaceuticals (JAZZ) PT Raised to $225 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $207.83 +1.35%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $225.00 (from $205.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- Jazz Pharmaceuticals (JAZZ) PT Raised to $300 at JPMorgan
- Insmed (INSM) PT Lowered to $195 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
